Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.35 |
| ▸ | STK3 | Q13188 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | LGMN | Q99538 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23379675 | 0.80 | GRM2 (0.43) | KEAP1MEN1USP2GAAKMT2A | |
| SCHEMBL15651048 | 0.74 | MEN1 (0.54) | KEAP1MEN1USP2GAAKMT2A | |
| SCHEMBL2712916 | 0.74 | KEAP1 (0.47) | KEAP1MEN1USP2GAAKMT2A | |
| SCHEMBL15650576 | 0.74 | MEN1 (0.54) | KEAP1MEN1USP2GAAKMT2A | |
| SCHEMBL23379678 | 0.71 | NUDT1 (0.52) | KEAP1MEN1USP2GAAKMT2A | |
| SCHEMBL23122834 | 0.71 | GRM2 (0.40) | ADORA2AADORA1CHEK1CHEK2DRD4 | |
| SCHEMBL23122832 | 0.71 | GRM2 (0.40) | ADORA2AADORA1CHEK1CHEK2DRD4 | |
| SCHEMBL29947224 | 0.69 | KEAP1 (0.46) | KEAP1MEN1USP2GAAKMT2A | |
| SCHEMBL29947345 | 0.69 | DRD4 (0.35) | DRD4 | |
| SCHEMBL127620 | 0.67 | KEAP1 (0.64) | KEAP1MEN1USP2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254083-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4337206-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022240992-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254083-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | TRPM2, TRPM7, TRPM8 | KEAP1 1619/4885MEN1 443/4885USP2 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.